Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
First Investment: 2022
If it were possible to watch drugs molecules at work under a microscope — seeing precisely how they act on different proteins inside cells — it would revolutionize drug development. Micrographia is doing just that. The company uses machine learning to analyze microscopy images at high throughput, allowing researchers and drug developers to unravel disease mechanisms at the subcellular level.
Explore Companies
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules